Could a diabetes drug boost lung cancer treatment? new trial aims to find out.
NCT ID NCT05445791
First seen Apr 23, 2026 · Last updated Jun 18, 2026 · Updated 8 times
Summary
This phase 3 trial tests whether adding metformin (a common diabetes medicine) to standard targeted therapy (tyrosine kinase inhibitors) can help people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). About 312 participants will receive either the combination or targeted therapy alone. The goal is to see if the combination delays cancer progression and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto Nacional de Cancerologia
RECRUITINGMexico City, 14080, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.